| Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ... Nature communications 11 (1), 5047, 2020 | 447 | 2020 |
| Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors SWJ Ember, JY Zhu, SH Olesen, MP Martin, A Becker, N Berndt, GI Georg, ... ACS chemical biology 9 (5), 1160-1171, 2014 | 244 | 2014 |
| CDK1 structures reveal conserved and unique features of the essential cell cycle CDK NR Brown, S Korolchuk, MP Martin, WA Stanley, R Moukhametzianov, ... Nature communications 6 (1), 1-12, 2015 | 190 | 2015 |
| Discovery of a potential allosteric ligand binding site in CDK2 S Betzi, R Alam, M Martin, DJ Lubbers, H Han, SR Jakkaraj, GI Georg, ... ACS chemical biology 6 (5), 492-501, 2011 | 190 | 2011 |
| Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains MP Martin, SH Olesen, GI Georg, E Schönbrunn ACS chemical biology 8 (11), 2360-2365, 2013 | 165 | 2013 |
| RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer RA Patel, KD Forinash, R Pireddu, Y Sun, N Sun, MP Martin, ... Cancer research 72 (19), 5025-5034, 2012 | 159 | 2012 |
| Identification and Characterization of an Irreversible Inhibitor of CDK2 E Anscombe, E Meschini, R Mora-Vidal, MP Martin, D Staunton, ... Chemistry & biology 22 (9), 1159-1164, 2015 | 112 | 2015 |
| Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ... Journal of medicinal chemistry 60 (5), 1746-1767, 2017 | 106 | 2017 |
| Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition DJ Wood, S Korolchuk, NJ Tatum, LZ Wang, JA Endicott, MEM Noble, ... Cell chemical biology 26 (1), 121-130. e5, 2019 | 102 | 2019 |
| A novel approach to the discovery of small‐molecule ligands of CDK2 MP Martin, R Alam, S Betzi, DJ Ingles, JY Zhu, E Schönbrunn Chembiochem 13 (14), 2128-2136, 2012 | 91 | 2012 |
| Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. GGI Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A J Med Chem, 2013 | 90 | 2013 |
| FragLites—minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation DJ Wood, JD Lopez-Fernandez, LE Knight, I Al-Khawaldeh, C Gai, S Lin, ... Journal of Medicinal Chemistry 62 (7), 3741-3752, 2019 | 84 | 2019 |
| Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors JY Zhu, RA Cuellar, N Berndt, HE Lee, SH Olesen, MP Martin, JT Jensen, ... Journal of medicinal chemistry 60 (18), 7863-7875, 2017 | 79 | 2017 |
| Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors HR Lawrence, MP Martin, Y Luo, R Pireddu, H Yang, H Gevariya, ... Journal of medicinal chemistry 55 (17), 7392-7416, 2012 | 75 | 2012 |
| A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A MP Martin, JY Zhu, HR Lawrence, R Pireddu, Y Luo, R Alam, S Ozcan, ... ACS chemical biology 7 (4), 698-706, 2012 | 67 | 2012 |
| Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors R Li, MP Martin, Y Liu, B Wang, RA Patel, JY Zhu, N Sun, R Pireddu, ... Journal of medicinal chemistry 55 (5), 2474-2478, 2012 | 62 | 2012 |
| Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2) R Pireddu, KD Forinash, NN Sun, MP Martin, SS Sung, B Alexander, ... MedChemComm 3 (6), 699-709, 2012 | 52 | 2012 |
| Structure-based discovery of cyclin-dependent protein kinase inhibitors MP Martin, JA Endicott, MEM Noble Essays in biochemistry 61 (5), 439-452, 2017 | 47 | 2017 |
| Molecular profiling and combinatorial activity of CCT 068127: a potent CDK 2 and CDK 9 inhibitor SR Whittaker, C Barlow, MP Martin, C Mancusi, S Wagner, A Self, E Barrie, ... Molecular Oncology 12 (3), 287-304, 2018 | 39 | 2018 |
| Discovery of diverse small‐molecule inhibitors of mammalian sterile20‐like kinase 3 (MST3) SH Olesen, JY Zhu, MP Martin, E Schönbrunn ChemMedChem 11 (11), 1137-1144, 2016 | 28 | 2016 |
Martin NobleProfessor of Structural Biology and Anticancer Drug Design在 ncl.ac.uk 的电子邮件经过验证
